Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tipranavir/Ritonavir in Hepatic Impairment
NCT02259855Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to 12 hours, Area under the concentration-time curve from 0 to 24 hours and 4 more. Started Jan 2006; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02259855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259855.